SCHEMBL7683262

SCHEMBL7683262

O=C(Cl)c1ccc(Br)c(Br)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
ALDH1A1 P00352 4/20 0.39
TSHR P16473 2/20 0.38
TTR P02766 1/20 0.38
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
HPGD P15428 4/20 0.35
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NOTUM Q6P988 1/20 0.34
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10882023 0.84 ALDH1A1 (0.38) MAPTALDH1A1TSHRTTRCES2
SCHEMBL2964948 0.82 TSHR (0.43) MAPTALDH1A1TSHRMEN1NPC1
SCHEMBL4900937 0.82 ALOX15 (0.48) MAPTALDH1A1TTRCES2HPGD
SCHEMBL320780 0.82 MAPT (0.55) MAPTALDH1A1TSHRHPGDCYP1A2
SCHEMBL2268166 0.82 ALDH1A1 (0.37) MAPTALDH1A1TSHRTTRCES2
SCHEMBL2266803 0.82 MAPT (0.38) MAPTALDH1A1TSHRTTRCES2
SCHEMBL19545230 0.80 MAPT (0.37) MAPTALDH1A1TSHRTTRCES2
SCHEMBL1707248 0.80 CHRNA1 (0.50) MAPTALDH1A1TSHRCES2CES1
SCHEMBL321581 0.80 CES2 (0.43) MAPTALDH1A1TSHRCES2CES1
SCHEMBL29477006 0.80 HPGD (0.56) MAPTALDH1A1TSHRHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281060-B2 Remodilins for airway remodeling and organ fibrosis THE UNIVERSITY OF CHICAGO (US) 2025-04-22 US disclosed
US-20240415851-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2024-12-19 US disclosed
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed
US-20220177422-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS THE UNIVERSITY OF CHICAGO (US) 2022-06-09 US disclosed
US-20220040207-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2022-02-10 US disclosed
EP-3946301-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS The University of Chicago (US) 2022-02-09 EP disclosed
WO-2020206118-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA THE UNIVERSITY OF CHICAGO (US) 2020-10-08 WO disclosed
WO-2020206109-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS THE UNIVERSITY OF CHICAGO (US) 2020-10-08 WO disclosed
WO-2020067593-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME 희성소재(주) 2020-04-02 WO disclosed
US-4192885-A Analgesic N-{2-[N'-(2-furylmethyl and 2-thienyl-methyl)-N'-alkylamino]cycloaliphatic}cyanobenzamides THE UPJOHN COMPANY (US) 1980-03-11 US disclosed
US-4179501-A Analgesic N-(2-aminocycloaliphatic)azidobenzamides THE UPJOHN COMPANY (US) 1979-12-18 US disclosed
US-4153717-A 260/332.2 R THE UPJOHN COMPANY (US) 1979-05-08 US disclosed
US-4152459-A Analgesic N-2-(aminocycloaliphatic)-hydroxy, alkoxy and (allylic)alkenyloxy-benzamides THE UPJOHN COMPANY (US) 1979-05-01 US disclosed
US-4148914-A Analgesic N-(2-aminocyclo aliphatic)cyanobenzamides THE UPJOHN COMPANY (US) 1979-04-10 US disclosed
US-4098904-A ANALGESIC N-(2-AMINOCYCLOALIPHATIC)BENZAMIDES THE UPJOHN COMPANY (US) 1978-07-04 US disclosed
US-3959217-A N-(halobenzoyl)-4,5-dibromo-3,6-methanohexahydrophthalimides VELSICOL CHEMICAL CORPORATION (US) 1976-05-25 US disclosed
US-3959216-A N-(Halobenzoyl) hexahalo-3,5-methanotetrahydrophthalimides VELSICOL CHEMICAL CORPORATION (US) 1976-05-25 US disclosed
US-3953397-A N-(halobenzoyl)-3,4-dibromohexahydrophthalimides VELSICOL CHEMICAL CORPORATION (US) 1976-04-27 US disclosed
US-3950307-A FIREPROOFING POLYMERS VELSICOL CHEMICAL CORPORATION (US) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220040207-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA HIF1AN, RHOXF2, HIF1A MAPT 4394/4885ALDH1A1 2857/4885TSHR 3276/4885
US-20220177422-A1 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS MYLK, MFAP1, FIBP MAPT 4699/4885ALDH1A1 3220/4885TSHR 3401/4885
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 MAPT 2934/4885ALDH1A1 3684/4885TSHR 4270/4885
US-12281060-B2 Remodilins for airway remodeling and organ fibrosis MYLK, MFAP1, FIBP MAPT 4699/4885ALDH1A1 3220/4885TSHR 3401/4885
US-20240415851-A1 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA HIF1AN, RHOXF2, HIF1A MAPT 4394/4885ALDH1A1 2857/4885TSHR 3276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.